Monthly Archives: May 2011

BRISBANE, Calif., May 25, 2011 /PRNewswire/ — InterMune (NASDAQ:ITMN – News) will outline the company’s corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, … Continue reading →

MALVERN, PA – May 16, 2011 – Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, presented data from a clinical study of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) at the 2011 American Thoracic … Continue reading →

BRISBANE, Calif., May 16, 2011 /PRNewswire via COMTEX/ — InterMune, Inc. (Nasdaq: ITMN) today announced that an oral presentation and a poster presentation related to the company’s development program for pirfenidone in idiopathic pulmonary fibrosis (IPF) will be presented at … Continue reading →

BRISBANE, Calif., May 13, 2011 /PRNewswire/ — InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung … Continue reading →

Results Human lungs contain undifferentiated human lung stem cells nested in niches in the distal airways. These cells are self-renewing, clonogenic, and multipotent in vitro. After injection into damaged mouse lung in vivo, human lung stem cells form human bronchioles, … Continue reading →

May 5 2011 Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011 MALVERN, Pa.–(BUSINESS WIRE)– Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that … Continue reading →